Development of diagnostic device to differentiate between bipolar and unipolar depression

双相情感障碍仅在英国就影响了240万人，据估计全球患病率约为2%，但40%的双相情感障碍患者被误诊为抑郁症，平均需要7.5年才能得到正确的诊断。这导致治疗无效，自杀风险增加，抗抑郁药引起的躁狂和更高的医疗费用，以及患者及其家属的生活质量下降。心理学的长期使命是改进心理健康状况的预防、诊断和治疗。我们最初的重点是改善双相情感障碍和抑郁症的初级保健诊断。最近由Psyomics和剑桥神经精神病学研究中心进行的研究已经确定了关键的生物标志物，通过干燥的血斑和数字筛选方法进行评估，可以区分这些疾病，并具有很强的预测性能。该项目将使Psyomics能够在这些结果的基础上，在2019年推出一个数字工具来支持分层，并在2020年推出一个两阶段的数字和生物诊断设备，以改善患者及其家属的诊断和临床结果。

Bipolar disorder affects 2.4m people in the UK alone and has an estimated prevalence of around 2% globally, yet 40% of patients with bipolar disorder are misdiagnosed with depression and it takes an average of 7.5 years for the correct diagnosis to be reached. This leads to ineffective treatments, increased suicide risk, antidepressant-induced mania and higher healthcare costs, as well decreased quality of life for patients and their families. The long-term mission for Psyomics is improved prevention, diagnosis and treatment of mental health conditions. Our initial focus is on improved diagnosis of bipolar disorder and depression in primary care Recent research conducted by Psyomics and the Cambridge Centre for Neuropsychiatric Research has identified key biomarkers, assessed in dried blood spots and via a digital-screening approach that can differentiate these conditions with a strong predictive performance. This project will enable Psyomics to build on these results with the aim of launching a digital-only tool to support stratification in 2019 and a two-stage digital and biological diagnostic device to improve diagnosis and clinical outcomes for patients and their families in 2020.